Chronic kidney disease (CKD) is the gradual loss of kidney function over a period of several years. Due to kidney failure, the organ’s function is severely impaired, which leads to accumulation of dangerous levels of waste and fluid in the body. Early detection can help prevent the progression of kidney to kidney failure. The treatment for CKD is aimed at stopping or slowing down the progression of the disease. Diuretics, RAS Blockade, β – Blockers, Calcium Channel Blockers etc. are some of the major drug used for the treatment of chronic kidney disease or its underlying cause.
Global Hypertension in CKD Market - Impact of the Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency. As the COVID-19 cases are surging, the risk for patients acquiring chronic kidney disease is also increasing. For instance, according to a study conducted in May 2020, by the researchers at Mount Sinai Health System, New York City, U.S., occurrence of kidney disease might increase as a post-COVID-19 effect in most of the COVID-19 positive patients. Moreover, according to the National Kidney Foundation, a study found that COVID-19 positive patients hospitalized in the span of March 11 and April 26, 2020, were likely to develop acute kidney injury (AKI) twice non-COVID patients.
COVID-19 pandemic is expected to hamper growth of the global hypertension in CKD market during the forecast period. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. These challenges are hindrances for developing new treatment for the patients suffering from hypertension with CKD.
The global hypertension in CKD market is estimated to be valued at US$ 191.8 Mn in 2020 and is expected to exhibit a CAGR of 10.6% over the forecast period (2020-2027).
Figure 1: Global Hypertension in CKD Market Share (%) Analysis, By Product Type, 2020
Market players are engaged in inorganic activities such as collaboration, in order to conduct research and development activities for various types of diseases, by combining their expertise and investment, which is expected to drive the growth of the global hypertension in CKD market
Key players are indulged in collaboration, in order to conduct clinical trials for different diseases. For instance, in 2019, Boehringer Ingelheim collaborated with Eli Lilly and Company, in order to develop and commercialize Jardiance (empagliflozin), for the treatment of type 2 diabetes, heart failure, and chronic kidney disease. Currently, the companies, jointly, are conducting clinical trials to evaluate the safety and efficacy of Jardiance in people suffering from heart failure or chronic kidney disease, including in people with and without type 2 diabetes.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 191.8 Mn |
| Historical Data for: | 2017 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 10.6% | 2027 Value Projection: | US$ 388.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Market players are indulged in launching new products for the treatment of Hyperphosphatemia in patients suffering from chronic kidney disease, which is expected to drive the growth of the global hypertension in CKD market over the forecast period
Increasing product launches by key players is expected to drive growth of the market over the forecast period. For instance, in 2018, Kissei Pharmaceutical Co., Ltd. launched P-TOL Granules (Sucroferric oxyhydroxide) 250 mg and 500 mg, in Japan for the treatment of hyperphosphatemia, in patients suffering from chronic kidney disease. According to the National Center for Biotechnology Information: 2018, hyperphosphatemia in dialysis patients is associated with vascular wall stiffness, which leads to hypertension.
Global Hypertension in CKD Market – Restraints
Lack of awareness about chronic kidney disease is the major factor that is expected to restrain growth of the global hypertension in CKD market over the forecast period. Despite the attempts made by governments in order to increase awareness among the population about chronic kidney disease (CKD) through different ways: such as dissemination of clinical practice guidelines and recommendations for patients with CKD or its risk factors, community awareness on events such as World Kidney Day, and free screening for high-risk individuals such as Kidney Early Evaluation Program (KEEP), it has been found that the awareness of CKD among the population remains unacceptably low.
For instance, in March 2018, according to the study published in the BMC Public Health, for chronic kidney disease evaluation, it was reported that the people in Australia have very poor understanding of chronic kidney disease (CKD) and only half of the participants knew about the availability of medications and also, their role in slowing down the worsening of CKD.
Global Hypertension in CKD Market – Regional Analysis
On the basis of region, the global hypertension in CKD market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global hypertension in CKD market, owing to the reimbursement policy for chronic kidney diseases in the region. For instance, on September 18, 2020, Centers for Medicare & Medicaid Services (CMS), a federal agency within the United States Department of Health and Human Services, announced the new Medicare model for the end-stage renal disease (ESRD), which is also called as the last stage of the chronic kidney disease. The model is End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model. The model encourages increased use of home dialysis and kidney transplants to help improve the quality of life of Medicare beneficiaries with ESRD. Moreover, this model will be implemented on January 1, 2021 and it is estimated that due to implementation of the model, US$ 23 million will be saved over a period of five and a half years.
Moreover, according to the National Institute of Diabetes and Digestive and Kidney Diseases: 2020, approximately 108 million people in the U.S. are suffering from high blood pressure or hypertension. According to the same source, the following pie chart depicts the factors responsible for the cause of kidney failure in patients suffering from chronic kidney disease, in the U.S.
Furthermore, Europe is also estimated to witness significant growth in the hypertension in CKD market, owing to increasing prevalence of chronic kidney diseases in the region. For instance, according to the article published in Lancet Journal: 2020, increasing prevalence of CKD was reported, in 2017, in different regions of Europe. The following graph depicts the number of people suffering from CKD in Europe.
Figure 2: Global Hypertension in CKD Market (US$ Mn), by Region, 2020
Global Hypertension in CKD Market – Competitive Landscape
Major players operating in the global hypertension in CKD market include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited.
Persons with CKD have significantly higher rates of morbidity, mortality, hospitalizations, and healthcare utilization. Chronic kidney disease may be caused due to comorbid conditions such as high blood pressure, etc. This can lead to buildup of metabolic wastes in patient’s blood and make them feel sick. Chronic kidney disease complications include high blood pressure, anemia (low blood count), weak bones, poor nutritional health, and nerve damage. Chronic kidney disease also increases the risk of developing heart and blood vessel diseases such as heart attack, stroke, etc. These problems may happen slowly over a long period of time.
Market Dynamics
Key players are involved in announcing their results for the clinical trials conducted for the antihypertensive drugs, in order to find the treatment for hypertension in patients suffering from chronic kidney disease. For instance, in 2018, Novartis International AG announced positive results for Entresto (sacubitril/valsartan). According to the clinical trials conducted by the company, it was found that Entresto (sacubitril/valsartan) helped to preserve kidney function in patients suffering from cardiovascular diseases. Moreover, Entresto (sacubitril/valsartan) belongs to angiotensin receptor blockers (ARBs) drug class.
The increasing number of patients undergoing dialysis treatment is expected to drive growth of the global hypertension in CKD market. For instance, according to the data published in the Indian Journal of Public Health (IJPH), in 2018, around 130,000 patients received dialysis treatment in India and the number increased by around 232 patients per million population in India as compared to 2017.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients